Literature DB >> 15608314

Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data.

M A Barón1, M A Khamashta, G R V Hughes, D P D'Cruz.   

Abstract

OBJECTIVES: To evaluate the prevalence of abnormal ankle-brachial indexes (ABIs), their relationship with other cardiovascular risk factors and/or the presence of antiphospholipid antibodies (aPL), and the clinical use of the ABI in patients with primary antiphospholipid syndrome (primary APS).
METHODS: An 8 MHz Doppler probe was used in the arms and legs to assess the ABI in 43 patients with primary APS (mean (SD) age 40.2 (7.9) years) and 49 healthy subjects (aged 41.0 (11.7)) matched for age and sex. Data on traditional cardiovascular risk factors, such as hypertension, hypercholesterolaemia, presence of diabetes mellitus, nephrotic syndrome or renal failure, smoking, and other variables, were collected at that time for all subjects. A ratio of the highest blood pressure from the posterior tibial or pedal arteries of each leg to the highest blood pressure from the brachial arteries <1.00 was considered abnormal.
RESULTS: Abnormal ABIs were found in 8/43 (19%) patients with primary APS and 2/49 (4%) controls (p = 0.026). No correlation between abnormal ABI and traditional cardiovascular risk factors nor with the presence of aPL was found.
CONCLUSION: Abnormal ABIs are more common in primary APS than in healthy controls, possibly indicating a subclinical atherosclerotic process in these patients.

Entities:  

Mesh:

Year:  2005        PMID: 15608314      PMCID: PMC1755181          DOI: 10.1136/ard.2003.016204

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography.

Authors:  Erick Alexanderson; Patricio Cruz; Angélica Vargas; Aloha Meave; Alejandro Ricalde; Jose A Talayero; José Luis Romero-Ibarra; Tovë M Goldson; Olga L Vera-Lastra; Gabriela Medina; Luis Jara; Mary-Carmen Amigo
Journal:  J Nucl Cardiol       Date:  2007-07-02       Impact factor: 5.952

Review 2.  Systemic lupus erythematosus.

Authors:  David P D'Cruz
Journal:  BMJ       Date:  2006-04-15

3.  Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study.

Authors:  C Christodoulou; M Zain; M L Bertolaccini; S Sangle; M A Khamashta; G R V Hughes; D P D'Cruz
Journal:  Ann Rheum Dis       Date:  2006-05       Impact factor: 19.103

4.  Prevalence of abnormal ankle brachial index in patients with primary Sjogren's syndrome.

Authors:  Satish M Rachapalli; Patrick D Kiely; Brian E Bourke
Journal:  Clin Rheumatol       Date:  2009-02-10       Impact factor: 2.980

5.  Impaired ankle-brachial index in antiphospholipid syndrome: Beyond the traditional risk factors.

Authors:  Simona Caraiola; Ciprian Jurcut; Alina Dima; Ruxandra Jurcut; Cristian Baicus; Anda Baicus
Journal:  J Clin Lab Anal       Date:  2018-07-10       Impact factor: 2.352

Review 6.  Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

Review 7.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 8.  Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings.

Authors:  Hasya Zinger; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 9.  Systemic antiphospholipid syndrome and atherosclerosis.

Authors:  Luis J Jara; Gabriela Medina; Olga Vera-Lastra
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 10.  Cardiovascular disease in lupus: insights and updates.

Authors:  Jason S Knight; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.